MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

To join this study, you would need to be at least 18 years old and have been diagnosed with aggressive B-cell non-Hodgkin lymphoma that has either come back or isn't responding to past treatments. You must have already had at least two different courses of standard treatment for your lymphoma.

It's important that you are generally well enough to take part, with your body's organs working adequately. Doctors will check for things like your blood counts, kidney function, and liver function. You also need to have at least one measurable area of lymphoma that doctors can track with scans.

There are also reasons why you might not be able to join. For example, if your lymphoma is in your brain or spinal cord, or if you've recently had other anti-cancer treatments within a couple of weeks, you might not be eligible. If you've had a specific type of treatment called a PIM inhibitor before, you wouldn't be able to participate either. The researchers will also make sure you don't have allergies to the study drugs or other health problems that could make the treatment unsafe for you.

If you decide to take part, you'll be assigned to one of two main groups, depending on your past treatments. You might receive MEN1703 alone or MEN1703 combined with glofitamab. The researchers will start with different doses to find the safest and most effective amount.

The treatment is given in cycles, with each cycle lasting 21 days. If you're in Group 1, you'll have treatment for a maximum of 12 cycles. If you're in Group 2, you'll continue treatment as long as the doctors see a benefit and the lymphoma isn't getting worse. During the study, you'll have regular hospital visits for check-ups, blood tests, and scans (like CT or PET-CT scans) to see how you're responding to the treatment and to monitor your general health. You may also need to provide a small sample of your lymph node tissue.